Description
An inhibitor of dihydroceramide desaturase (IC50 = 2.32 µM); promotes the generation of ROS, degradation of MCL-1, and cleavage of PKCδ; selectively activates RARγ at 5-20 µM; inhibits the growth of Caov-3, OVCAR-3, and SKOV3 ovarian cancer cells (IC50s = 3.7, 6.9, and 8.2 µM, respectively); increases activity of SPT by 1.75-fold and induces caspase-dependent apoptosis in BMEC cells (IC50 = 2.4 µM); prevents lipid-induced reductions in insulin-stimulated glucose uptake in isolated rat soleus muscle; reduces liver and soleus muscle neutral lipid content and inhibits high-fat diet-induced increases in dihydroceramide desaturase transcription at 10 mg/ml,,
Formal name: N-(4-hydroxyphenyl)-retinamide
Synonyms: 4-HPR|4-Hydroxy(phenyl)retinamide|MK-4016|Retinoic Acid p-hydroxyphenylamide|Ro 22-4667
Molecular weight: 391.6
CAS: 65646-68-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Activators||Product Type|Biochemicals|Small Molecule Inhibitors|Fatty Acid Metabolism||Product Type|Biochemicals|Small Molecule Inhibitors|Sphingolipid Turnover||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Endocrinology & Metabolism|Hormones & Receptors|RARs, RORs, & RXRs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes
